SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus clinical pipeline, particularly reported early REGAIN results in recurrent glioblastoma and the FDA-cleared trial expansion, alongside completed enrollment in its pancreatic cancer IMPACT study and further data milestones ahead. Traders are largely bullish on the catalysts, though some note share-price resistance and volatility; the early clinical signals remain preliminary.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention ahead of its quarterly report, with traders focused on whether resilient smaller-project demand can offset a sluggish housing market and weak big-ticket renovations. Bulls cite the recent rally and technical momentum, while bears question its durability amid high rates and soft project demand.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on the Phase 3 APPROACH topline readout for Heluss HLP003 depression treatment, a binary catalyst traders see as a potential test of its adjunctive approach and proposed shorter clinic times. Bulls anticipate differentiated results, while skeptics cite efficacy and dilution risks; discussion also reflects concern that a reported Nature Neuroscience paper could challenge durability claims and that Usona may add competitive pressure.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for Summits ivonescimab application, saying the PFS benefit did not support approval without statistically significant overall-survival evidence. Traders are reacting with sharp bearish concern, while some holders argue the setback is limited to this indication and point to the HARMONi-3 readout and broader pipeline as remaining catalysts.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and volatile rebound are driving discussion, with traders split over whether support in the low-$60,000s marks a bottom or another leg lower; many describe the move as liquidation-driven. Community explanations also point to ETF selling, the Binance hack and rate concerns, while others expect an oversold bounce.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys upcoming quarterly results are the main focus, with traders weighing streaming profitability and parks performance against softer Asia parks and recent movie misses. Some expect earnings to support the stock, while others are cautious about its stalled move near resistance.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

The FAAs nationwide ground stop after an air-traffic-control communications failure, followed by continuing flight delays and cancellations, is driving attention to Delta and airline peers. Traders debate whether the disruption will materially hurt operations and earnings or prove temporary now that the stop has been lifted.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimunes FDA approval of TUDRIQEV for advanced melanoma and its commercial launch are driving attention, with traders focused on early prescribing and access as signs of potential uptake. The rally has also fueled short-squeeze talk, while bears question the drugs demand, competition, and whether launch execution can justify the valuation.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Promising early CTX310 and zugo-cel clinical updates are drawing attention, but traders are divided as the shares have struggled to respond: bulls see pipeline validation alongside growing CASGEVY uptake, while skeptics point to small datasets, long development timelines and persistent weak price action.

JasmyCoin (JASMY) is a cryptocurrency launched in 2016and operates on the Ethereum platform. JasmyCoin has a current supply of 50,000,000,000 with 49,444,999,677.16957912 in circulation. The last known price of JasmyCoin is 0.00312867 USD and is down -5.82 over the last 24 hours. It is currently trading on 374 active market(s) with $10,034,947.48 traded over the last 24 hours. More information can be found at https://www.jasmy.co.jp/en_company.html.

JasmyCoin

A reported JasmyAppBank MOU to develop AI and data services, including the Money Twin concept, is fueling renewed optimism alongside a technical rebound. Bulls see potential utility through Jasmys data and blockchain infrastructure, while skeptics say real adoption and usage remain unproven.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Sorry_For_Your_Loss

Sorry_For_Your_Loss